Abstract
Hypoxic solid tumors induce the stabilization of hypoxia-inducible factor 1 alpha (HIF1α), which stimulates the expression of many glycolytic enzymes and hypoxia-responsive genes. A high rate of glycolysis supports the energetic and material needs for tumors to grow. Fructose-1,6-bisphosphate aldolase A (ALDOA) is an enzyme in the glycolytic pathway that promotes the expression of HIF1α. Therefore, inhibition of ALDOA activity represents a potential therapeutic approach for a range of cancers by blocking two critical cancer survival mechanisms. Here, we present a luminescence-based strategy to determine ALDOA activity. The assay platform was developed by integrating a previously established ALDOA activity assay with a commercial NAD/NADH detection kit, resulting in a significant ('12-fold) improvement in signal/background (S/B) compared with previous assay platforms. A screening campaign using a mixture-based compound library exhibited excellent statistical parameters of Z′ ('0.8) and S/B (~20), confirming its robustness and readiness for high-throughput screening (HTS) application. This assay platform provides a cost-effective method for identifying ALDOA inhibitors using a large-scale HTS campaign.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1038-1046 |
| Number of pages | 9 |
| Journal | SLAS Discovery |
| Volume | 25 |
| Issue number | 9 |
| DOIs | |
| State | Published - Oct 1 2020 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 Society for Laboratory Automation and Screening.
Keywords
- NADH
- aldolase A
- anticancer
- high-throughput screening
- luminescence